57 related articles for article (PubMed ID: 15166618)
1. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
2. Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy.
Bradford KL; Liu S; Krajinovic M; Ansari M; Garabedian E; Tse J; Wang X; Shaw KL; Gaspar HB; Candotti F; Kohn DB
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1819-1827. PubMed ID: 32653625
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Cremers S; Schoemaker R; Bredius R; den Hartigh J; Ball L; Twiss I; Vermeij P; Vossen J
Br J Clin Pharmacol; 2002 Apr; 53(4):386-9. PubMed ID: 11966670
[TBL] [Abstract][Full Text] [Related]
4. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing.
Hughes JH; Long-Boyle J; Keizer RJ
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):279-288. PubMed ID: 38520573
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
[TBL] [Abstract][Full Text] [Related]
6. Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.
Neely M; Philippe M; Rushing T; Fu X; van Guilder M; Bayard D; Schumitzky A; Bleyzac N; Goutelle S
Ther Drug Monit; 2016 Jun; 38(3):332-42. PubMed ID: 26829600
[TBL] [Abstract][Full Text] [Related]
7. Limited Sampling Strategies for Estimating Busulfan Area Under the Concentration-Time Curve: Based on Peak and Trough Concentrations in Saliva.
Xu B; Zhou J; Zheng Y; Xu R; Liu Q; Li D; Liu M; Wu X
J Clin Pharmacol; 2024 Jan; 64(1):58-66. PubMed ID: 37697452
[TBL] [Abstract][Full Text] [Related]
8. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients.
Ben Hassine K; Daali Y; Gloor Y; Nava T; Théorêt Y; Krajinovic M; Bittencourt H; Satyanarayana Uppugunduri CR; Ansari M
Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38885146
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor.
Vethe NT; Andersen AM; Gedde-Dahl T; Büchner J; Bergan S
Ther Drug Monit; 2024 Jun; 46(3):416-417. PubMed ID: 38648662
[No Abstract] [Full Text] [Related]
10. Therapeutic drug monitoring of busulfan in transplantation.
Russell JA; Kangarloo SB
Curr Pharm Des; 2008; 14(20):1936-49. PubMed ID: 18691105
[TBL] [Abstract][Full Text] [Related]
11. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
[TBL] [Abstract][Full Text] [Related]
12. Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective.
Briki M; André P; Thoma Y; Widmer N; Wagner AD; Decosterd LA; Buclin T; Guidi M; Carrara S
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111768
[TBL] [Abstract][Full Text] [Related]
13. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
Shukla P; Goswami S; Keizer RJ; Winger BA; Kharbanda S; Dvorak CC; Long-Boyle J
Front Pharmacol; 2020; 11():888. PubMed ID: 32714184
[TBL] [Abstract][Full Text] [Related]
14. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor (G-CSF) promotes spermatogenic regeneration from surviving spermatogonia after high-dose alkylating chemotherapy.
Kotzur T; Benavides-Garcia R; Mecklenburg J; Sanchez JR; Reilly M; Hermann BP
Reprod Biol Endocrinol; 2017 Jan; 15(1):7. PubMed ID: 28077131
[TBL] [Abstract][Full Text] [Related]
16. Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.
Stockmann C; Barrett JS; Roberts JK; Sherwin C
CPT Pharmacometrics Syst Pharmacol; 2015 Nov; 4(11):630-40. PubMed ID: 26783499
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Shea TC; Walko C; Chung Y; Ivanova A; Sheets J; Rao K; Gabriel D; Comeau T; Wood W; Coghill J; Armistead P; Sarantopoulos S; Serody J
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2129-2135. PubMed ID: 26210442
[TBL] [Abstract][Full Text] [Related]
18. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Nagler A; Labopin M; Gorin NC; Ferrara F; Sanz MA; Wu D; Gomez AT; Lapusan S; Irrera G; Guimaraes JE; Sousa AB; Carella AM; Vey N; Arcese W; Shimoni A; Berger R; Rocha V; Mohty M
Haematologica; 2014 Aug; 99(8):1380-6. PubMed ID: 24816236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
